- Home
- MLSS vs IFRX Comparison
MLSS vs IFRX Comparison
Compare MLSS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLSS
- IFRX
- Stock Information
- Founded
- MLSS 1989
- IFRX 2007
- Country
- MLSS United States
- IFRX Germany
- Employees
- MLSS N/A
- IFRX N/A
- Industry
- MLSS Industrial Specialties
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- MLSS Health Care
- IFRX Health Care
- Exchange
- MLSS Nasdaq
- IFRX Nasdaq
- Market Cap
- MLSS 74.9M
- IFRX 65.8M
- IPO Year
- MLSS 1995
- IFRX 2017
- Fundamental
- Price
- MLSS $0.67
- IFRX $0.80
- Analyst Decision
- MLSS Buy
- IFRX Strong Buy
- Analyst Count
- MLSS 1
- IFRX 4
- Target Price
- MLSS $1.25
- IFRX $7.75
- AVG Volume (30 Days)
- MLSS 101.2K
- IFRX 282.5K
- Earning Date
- MLSS 08-13-2025
- IFRX 08-07-2025
- Dividend Yield
- MLSS N/A
- IFRX N/A
- EPS Growth
- MLSS N/A
- IFRX N/A
- EPS
- MLSS N/A
- IFRX N/A
- Revenue
- MLSS $8,613,503.00
- IFRX $140,242.00
- Revenue This Year
- MLSS $29.14
- IFRX N/A
- Revenue Next Year
- MLSS $20.19
- IFRX $6,309.47
- P/E Ratio
- MLSS N/A
- IFRX N/A
- Revenue Growth
- MLSS N/A
- IFRX 30.90
- 52 Week Low
- MLSS $0.57
- IFRX $0.71
- 52 Week High
- MLSS $1.39
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- MLSS 28.44
- IFRX 37.46
- Support Level
- MLSS $0.61
- IFRX $0.78
- Resistance Level
- MLSS $0.81
- IFRX $0.83
- Average True Range (ATR)
- MLSS 0.06
- IFRX 0.04
- MACD
- MLSS -0.02
- IFRX 0.03
- Stochastic Oscillator
- MLSS 28.57
- IFRX 52.40
About MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.